Skip to main content

Charles River Laboratories International, Inc.

corporate_fare Company Profile

Charles River Laboratories International, Inc.

CRL·NYSE·Industrial Applications And Services·CIK 0001100682

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services globally, operating in the United States, Europe, Canada, the Asia Pacific, and other international markets. The company is structured into three main segments. The Research Models and Services segment produces and sells rodents, including purpose-bred rats and mice, for research use. This segment also offers services supporting research models, such as genetically engineered models and services, insourcing solutions, and research animal diagnostic services, and is involved in the development and production of cell therapies. The Discovery and Safety Assessment segment provides in vitro and in vivo discovery services for novel drugs, molecule compounds, oligonucleotides, biotherapeutics, and antibodies, delivering preclinical candidates for safety assessment. It also offers safety assessment services, including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics, alongside vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized biologics testing outsourced by pharmaceutical and biotechnology companies, and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles for its contract development and manufacturing organization, and a strategic alliance with Francis Crick Institute (Crick), Inc. for Antibody-Drug Conjugate (ADC) drug discovery and development. Founded in 1947, Charles River Laboratories International, Inc. is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc. (NYSE:CRL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for CRL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Charles River Labs Announces $510M Accretive Acquisition, Positive Q4 Demand, and Favorable 2026 Outlook
  • Charles River Labs Announces CEO Transition: Birgit Girshick to Succeed James Foster

Financial Snapshot

Fiscal year ended December 27, 2025
Revenue
$4.02B
Net Income
-$144.34M
Diluted EPS
-$2.91
Op. Cash Flow
$737.65M
Free Cash Flow
$518.49M
Operating Income
$25.16M
Cash & Equivalents
$213.77M
Total Debt
$166K
Debt / Equity
0.00×
Net Margin
-3.6%
Shares Outstanding
49.22M sh
Source: 10-K · filed 2026-02-18 · accession 0001100682-26-000022
$315.43 +0.35% today
52-week range · as of 2026-11-04 $146.19 – $379.63
Market cap
$15.06B
Volume
1.2M (1.0× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRL - Filings & News (Page 2)

CRL
Jan 13, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $218.99
Real-time Price: $315.43 info
Change: +$96.44 (+44%) info
Market Cap: $15.061B info
CRL
Jan 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $220.91
Real-time Price: $315.43 info
Change: +$94.52 (+43%) info
Market Cap: $15.061B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets